Does the media refer more to PRAX or BIIB?

In the previous week, Biogen had 21 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for Biogen and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Biogen's score of 0.90 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 9 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or INSM?

In the previous week, Insmed had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Insmed and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Insmed's score of 0.84 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or BNTX?

In the previous week, BioNTech had 28 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 29 mentions for BioNTech and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat BioNTech's score of 0.14 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer INCY or PRAX?

In the previous week, Incyte had 11 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Incyte and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Incyte's score of 0.75 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Praxis Precision Medicines (PRAX) Competitors

$298.95 -11.52 (-3.71%)

Closing price 04:00 PM Eastern

Extended Trading

$297.81 -1.14 (-0.38%)

As of 08:00 PM Eastern

Compare

PRAX vs. ALNY, BIIB, INSM, BNTX, and INCY

Should you buy Praxis Precision Medicines stock or one of its competitors? Praxis Precision Medicines's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals currently has a consensus price target of $367.20, indicating a potential upside of 53.28%. Praxis Precision Medicines has a consensus price target of $612.42, indicating a potential upside of 104.86%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 10 mentions for Alnylam Pharmaceuticals and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Alnylam Pharmaceuticals' score of 0.32 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Praxis Precision Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.63	$313.75M	$5.38	44.53
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A

Summary

Alnylam Pharmaceuticals beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Biogen?

Praxis Precision Medicines (NASDAQ:PRAX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Biogen had 21 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for Biogen and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Biogen's score of 0.90 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biogen	9 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Praxis Precision Medicines' net margin of 0.00%. Biogen's return on equity of 11.18% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
Biogen	$9.89B	3.22	$1.29B	$5.65	38.14

Praxis Precision Medicines has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $612.42, suggesting a potential upside of 104.86%. Biogen has a consensus target price of $230.14, suggesting a potential upside of 6.79%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biogen beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Insmed?

Praxis Precision Medicines (NASDAQ:PRAX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Praxis Precision Medicines presently has a consensus price target of $612.42, suggesting a potential upside of 104.86%. Insmed has a consensus price target of $204.91, suggesting a potential upside of 70.76%. Given Praxis Precision Medicines' higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Insmed had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Insmed and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Insmed's score of 0.84 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Praxis Precision Medicines' return on equity of -34.15% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Insmed	-76.94%	-123.94%	-44.30%

Praxis Precision Medicines has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
Insmed	$606.42M	43.21	-$1.28B	-$4.11	N/A

Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Summary

Praxis Precision Medicines beats Insmed on 12 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to BioNTech?

Praxis Precision Medicines (NASDAQ:PRAX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, BioNTech had 28 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 29 mentions for BioNTech and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat BioNTech's score of 0.14 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
BioNTech	-63.54%	-6.86%	-6.00%

Praxis Precision Medicines has higher earnings, but lower revenue than BioNTech. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
BioNTech	$3.25B	7.48	-$1.29B	-$7.83	N/A

Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $612.42, suggesting a potential upside of 104.86%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 31.17%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Praxis Precision Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does Praxis Precision Medicines compare to Incyte?

Incyte (NASDAQ:INCY) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Incyte has a net margin of 27.71% compared to Praxis Precision Medicines' net margin of 0.00%. Incyte's return on equity of 29.93% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Incyte presently has a consensus target price of $124.05, indicating a potential downside of 1.01%. Praxis Precision Medicines has a consensus target price of $612.42, indicating a potential upside of 104.86%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

Incyte has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.94	$1.29B	$7.85	15.96
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A

97.0% of Incyte shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

In the previous week, Incyte had 11 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Incyte and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.62 beat Incyte's score of 0.75 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Incyte beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRAX vs. The Competition

Export

Metric	Praxis Precision Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.67B	$3.91B	$7.26B	$13.71B
Dividend Yield	N/A	3.64%	2.57%	12.94%
P/E Ratio	-23.12	14.08	273.80	25.39
Price / Sales	976.22	1,407.73	644.02	89.12
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	8.58	15.45	10.45	6.33
Net Income	-$303.27M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-10.65%	-1.25%	0.88%	1.20%
1 Month Performance	-19.17%	-1.67%	0.03%	-2.04%
1 Year Performance	560.96%	35.67%	18.28%	5.41%

Praxis Precision Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRAX Praxis Precision Medicines	3.0883 of 5 stars	$298.95 -3.7%	$612.42 +104.9%	+605.1%	$8.67B	$8.55M	N/A	110	Positive News High Trading Volume
ALNY Alnylam Pharmaceuticals	4.3462 of 5 stars	$266.11 flat	$386.14 +45.1%	-45.7%	$35.61B	$3.71B	49.46	2,770
BIIB Biogen	3.3384 of 5 stars	$220.83 flat	$228.50 +3.5%	+51.2%	$32.63B	$9.89B	39.08	7,500
INSM Insmed	3.2468 of 5 stars	$126.29 flat	$205.52 +62.7%	-14.4%	$27.58B	$606.42M	N/A	1,664	Analyst Forecast
BNTX BioNTech	4.3579 of 5 stars	$103.76 flat	$126.00 +21.4%	+0.5%	$26.24B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRAX) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Summary

How does Praxis Precision Medicines compare to Biogen?

Summary

How does Praxis Precision Medicines compare to Insmed?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Summary

How does Praxis Precision Medicines compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Competitors

PRAX vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Praxis Precision Medicines compare to Alnylam Pharmaceuticals?

Do institutionals and insiders have more ownership in ALNY or PRAX?

Do analysts prefer ALNY or PRAX?

Does the media prefer ALNY or PRAX?

Is ALNY or PRAX more profitable?

Which has more risk & volatility, ALNY or PRAX?

Which has preferable valuation and earnings, ALNY or PRAX?

Summary

How does Praxis Precision Medicines compare to Biogen?

Does the media refer more to PRAX or BIIB?

Is PRAX or BIIB more profitable?

Which has preferable valuation & earnings, PRAX or BIIB?

Which has more risk and volatility, PRAX or BIIB?

Do analysts recommend PRAX or BIIB?

Do insiders and institutionals have more ownership in PRAX or BIIB?

Summary

How does Praxis Precision Medicines compare to Insmed?

Do insiders and institutionals hold more shares of PRAX or INSM?

Do analysts recommend PRAX or INSM?

Does the media favor PRAX or INSM?

Is PRAX or INSM more profitable?

Which has stronger valuation & earnings, PRAX or INSM?

Which has more risk and volatility, PRAX or INSM?

Summary

How does Praxis Precision Medicines compare to BioNTech?

Does the media refer more to PRAX or BNTX?

Is PRAX or BNTX more profitable?

Which has preferable valuation and earnings, PRAX or BNTX?

Which has more volatility & risk, PRAX or BNTX?

Do analysts rate PRAX or BNTX?

Do insiders & institutionals have more ownership in PRAX or BNTX?

Summary

How does Praxis Precision Medicines compare to Incyte?

Is INCY or PRAX more profitable?

Do analysts rate INCY or PRAX?

Which has higher valuation and earnings, INCY or PRAX?

Do insiders & institutionals hold more shares of INCY or PRAX?

Which has more risk and volatility, INCY or PRAX?

Does the media prefer INCY or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX vs. The Competition

Praxis Precision Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools